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Recently, much attention has been given to pulmonary drug delivery by means of nanosized systems to treat both local and
systemic diseases. Among the diﬀerent materials used for the production of nanocarriers, chitosan enjoys high popularity due to its
inherent characteristics such as biocompatibility, biodegradability, and mucoadhesion, among others. Through the modification
of chitosan chemical structure, either by the addition of new chemical groups or by the functionalization with ligands, it is possible
to obtain derivatives with advantageous and specific characteristics for pulmonary administration. In this paper, we discuss
the advantages of using chitosan for nanotechnology-based pulmonary delivery of drugs and summarize the most recent and
promising modifications performed to the chitosan molecule in order to improve its characteristics.
1. Introduction
Alongside the successful market launch of diﬀerent products
over the last decades, a continuous eﬀort to formulate deliv-
ery systems for the pulmonary administration of a wide vari-
ety of drugs has been extensively described in the literature
[1, 2]. The particular anatomical, physiological, and patho-
physiological features of the respiratory tract pose enormous
challenges that need to be overcome in order to obtain eﬀec-
tive lung deposition, uniform distribution, in loco retention
(main challenge is to circumvent mucocilliary clearance),
and stability (particularly to enzymatic degradation) of ther-
apeutic agents [1, 3].
Nevertheless, particular attention has been dedicated not
only to drugs themselves but also to excipients required to im-
prove the bioavailability of drugs administered pulmonarily.
In this context, excipients that could transiently enhance the
absorption of drugs are on the spot. Chitosan, a polysaccha-
ride with structural characteristics similar to glucosamines
and obtained by the alkaline deacetylation of chitin, derived
from the exoskeleton of crustaceans, is one of such appealing
excipients.
The safety and tolerability of chitosan are synergistic
characteristics towards its application in drug delivery by dif-
ferent administration routes. Despite the natural properties,
some drawbacks are associated with the poor solubility at
physiologic pH and the passive targeting eﬀect. Thus, chem-
ical modifications of chitosan by conjugating various func-
tional groups allow the control of the hydrophilicity and the
solubility at neutral and basic pH and open new opportuni-
ties to expand the application of this biopolymer.
2 International Journal of Carbohydrate Chemistry
In this paper, we revise some of the most recent and pro-
mising modifications performed to chitosan with special
focus on its employment in the pulmonary delivery of drugs.
2. Advantages of Chitosan for Pulmonary
Delivery of Drugs
Chitosan possesses diﬀerent beneficial properties that make
it an attractive option for designing adequate dosage forms
and advanced drug delivery systems to be administered to
or through the lung. General advantages include the well-
established biocompatibility and biodegradability of chi-
tosan [4]. Moreover, antimicrobial [5] and antioxidant [6, 7]
activities have been reported for diﬀerent types of chitosan
and derivatives, which can also be regarded as potentially
useful for the development of pulmonary drug delivery sys-
tems. The processability of chitosan and several derivatives
allow obtaining diﬀerent types of systems (powders or well-
structuredmicro- and nanocarriers) that can be optimized in
order to present optimal aerodynamic particle diameters for
lung deposition and retention [8–11]. Also, the presence of
reactive amine groups grants chitosan the chemical versatility
for modification and functionalization (Figure 1) [12].
Chitosan is a cationic mucoadhesive polymer. The ability
to establish ionic, hydrogen, and hydrophobic bonding with
negatively charged chains of mucin [13], the structural com-
ponent of mucus fluids, evidences its potential for increasing
lung retention of drug carriers comprising chitosan. The
mucoadhesive properties of the native polymer can be
further increased by chemical modification. In particular,
thiolation (i.e., attachment of side chains containing thiol
groups) has been proved an interesting strategy for this
last purpose [14]. In one recent study, Makhlof et al. [15]
reported on the enhanced mucoadhesion of nanoparticles
composed of thioglycolic acid-glycol chitosan, as compared
to nanoparticles based on the nonthiolated polymer (i.e., gly-
col chitosan), after intratracheal administration to rats. More
importantly, the increment in pulmonary mucoadhesion
observed by these researchers was correlated with the greater
bioavailability of calcitonin when this peptide was associated
with nanoparticles. However, mucoadhesive properties of
chitosan and derivatives may also be detrimental, since
adhesion of delivery systems at the upper respiratory tract
and airways can also occur, thus limiting the amount of
carrier that eﬀectively reaches the deep lung. Formulating
scientists should keep this phenomenon in mind when
developing chitosan-based systems.
Chitosan is able to enhance absorption of drugs by the
paracellular route, in particular macromolecules, due to the
transiently disruption of tight junctions (Figure 2) [16].
In order to confirm this eﬀect in pulmonary drug deliv-
ery, Yamamoto et al. [17] performed in vivo experiments in
guinea pigs by comparing the pulmonary absorption of dif-
ferent model drugs in solution (carboxyfluorescein and fluo-
rescein isothiocyanate dextran with molecular weight (MW)
varying from 4 to 70 kDa), either in the presence or absence
of chitosan. Results showed significantly higher perme-
ation for all the investigated model drugs in the presence
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Figure 1: Chemical structure of chitosan, comprising N-acetyl-D-
glucosamine (right) and D-glucosamine (left) units.
of chitosan, as assessed by blood drug levels. Absorption
enhancement was higher for higher MW isothiocyanate
dextran, which is mainly absorbed by the paracellular route,
providing evidence for the mechanism of intercellular tight
junction disruption.
Toxicological data on chitosan has been extensively re-
viewed and is regarded to be favorable when considering its
use as a pharmaceutical excipient [4]. In the particular case
of pulmonary drug delivery, in vitro cytotoxicity experiments
were conducted for chitosan presenting diﬀerent degrees of
deacetylation and MW using human embryonic lung cells
(L132 cells) [18]. Results revealed that chitosan presented
50% inhibitory concentration (IC50) values higher than
1mg/mL. Studies have also been conducted for derivatives
of chitosan or chitosan-based formulations intended for
pulmonary administration. For instance, Grenha et al. [19]
showed that chitosan nanoparticles obtained by ionotropic
gelation with tripolyphosphate and entrapped in mannitol
microparticles presented reduced toxicity (concentrations of
up to 1.3mg/mL of nanoparticles were tested) to adenocarci-
noma epithelial lung cell lines (Calu-3 and A549). In another
study conducted in A549 cells, stearic acid-g-chitosan oligo-
saccharide micelles presented an IC50 value of approximately
369 μg/mL [20]. However, chitosan and derivatives may also
induce immune responses by lung cells/tissue. In an in vitro
study, Calu-3 cells exposed to chitosan microparticles were
able to elicit the release of inflammatory cytokines (IL-2 and
IL-8) [21]. Florea et al. [22] performed in vivo studies in rats
by administering intratracheally chitosan and two brands
of N-trimethylated chitosan (TMC), presenting diﬀerent
degrees of substitution (20% and 60%). Histopathological
analysis of lung tissue showed that chitosan elicited neu-
trophil infiltration and structural damage in the lung paren-
chyma; however, this eﬀect may be attributable not to the
inherent toxicity of chitosan but most probably to the phys-
ical obstruction of the bronchioles due to higher viscosity
of the chitosan formulation, thus causing local asphyxiation.
In the case of TMC, these eﬀects were milder, which could
be associated with lower viscosity when compared to chi-
tosan. Comparable inflammatory eﬀects were also observed
in rats after the intratracheal administration of chitosan
microparticles [23]. Moreover, the production of sev-
eral proinflammatory cytokines has been observed for
hydrophobically modified glycol-chitosan nanoparticles in
vivo after intratracheal instillation in mice [24]. Even if
generally regarded as detrimental, immune stimulation may
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Figure 2: Eﬀect of chitosan on the absorption of drugs by the paracellular route. (a) Normal epithelium. (b) Transient disruption of tight
junctions by chitosan with enhancement of drug absorption. 1: represents the drug, 2: represents the tight junction, and 3: represents
chitosan.
be a particularly interesting feature for vaccine development
[25].
3. Chitosan and Chitosan-Grafting Copolymers
for Nanoparticle-Based Pulmonary Drug
Delivery Systems
The first nanoparticles with drug delivery purposes began in
the late 1960s [26]. Nanoparticles are solid colloidal particles
made of macromolecular materials ranging in size from 1 to
1000 nm, although sometimes the term identifies particles
in the 1 to 200 nm range, depending on the application
field [27]. For pharmaceutical and medical applications,
nanoparticles can be used therapeutically as carriers, either
by dissolving, entrapping, or encapsulating the active sub-
stance (drug or biologically active material) or by adsorbing
or attaching the active substance on the surface.
Diﬀerent nanoparticles have been developed for pulmo-
nary administration of various drugs to treat diseases such as
tuberculosis (TB) [28–30] and other pulmonary infections
[31] and diseases [31, 32]. Since this natural polymer oﬀers
remarkable advantages over other natural and synthetic
polymeric carriers, in this section, we will focus on chitosan-
grafting-based polymeric nanoparticles as drug carriers.
3.1. Trimethyl Chitosan (TMC). Trimethylated chitosan
(TMC) is a partially quaternized chitosan derivative that is
freely soluble in aqueous solutions over a wide range of pH
as compared to other chitosan salt derivatives (Figure 3).
TMC is obtained by reductive methylation of chitosan using
methyl iodide in the presence of a strong base (e.g., NaOH)
at 60◦C [33, 34]. This soluble chitosan derivative has mu-
coadhesive properties and displays excellent absorption-
enhancing properties, even at neutral pH [35, 36]. This capa-
bility as enhancer is due to opening the tight junctions
between adjacent epithelial cells through interactions be-
tween the protonated (positively charged) amino groups on
the C-2 position and the negatively charged sites on the
cell membrane and/or in the tight junctions [37]; TMC has
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Figure 3: Chemical structure of trimethyl chitosan (showing the
modification at the D-glucosamine unit).
positive charges, independently of the pH, at all degrees of
quaternization [38]. An increase in the degree of quaterniza-
tion leads to increase of the permeation-enhancing eﬀect of
TMC [34].
TMC-based nanoparticles have consistently shown their
feasibility for mucosal immunization. Studies have addressed
oral vaccination against Helicobacter pylori using urease [39].
Intranasal administration of the influenza antigen elicited
local and systemic immune responses in mice [40]. A similar
approach was assessed with the tetanus toxoid by nasal
instillation in mice [41]. TMC nanoparticles were loaded
with FTIC ovalbumin, and their transport across the nasal
epithelium of rat was studied [42]. A recent study has also
shown that the delivery of the model antigen ovalbumin
(OVA) to the cervical lymph nodes in a nanoconjugated
form with TMC (∼30 nm diameter) was twice more eﬀective
than the nasal administration of ovalbumin-containing TMC
nanoparticles with size of one order of magnitude greater
(∼300 nm diameter) [43]. In turn, synergistic eﬀects of the
TLR9 ligand CpG in TMC particles have been reported after
nasal vaccination [44].
Florea et al. observed that 20% and 60%N-TMC (TMC20
and TMC60) enhanced the permeation of octreotide in vitro
by 21-, 16-, and 30-fold. Also, the bioavailability was en-
hanced by 2.4-, 2.5-, and 3.9-fold, respectively. Cell viability
and histology studies showed that the TMCs are safer than
chitosan and that Calu-3 cell monolayers are a valuable
model for predicting the paracellular transport kinetics in
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the airway epithelia. Taking into account these results, they
sustain that cationic polysaccharides are promising enhan-
cers for peptide drug absorption with prospect for sustained-
release formulations [22]. Slutter et al. reported on the con-
jugation of an antigen, OVA, to TMC and the preparation of
nanoparticles for subunit vaccination. The uptake of TMC-
OVA conjugates by dendritic cells was similar to the uptake
of TMC/OVA nanoparticles and over 5-fold greater when
compared to a solution of OVA and TMC. Conjugation of the
antigen to TMC and TMC/OVA is therefore a viable strategy
to increase the immunogenicity of subunit vaccines [45].
3.2. Carboxymethyl Chitosan (CMC). CMC is prepared by
adding a carboxymethyl group in the structure of chitosan.
This modification increases its solubility in neutral and basic
solutions without aﬀecting other important characteristics
[46]. CMC is prepared by carboxymethylation of the hydro-
xyl and amine chitosan groups [47]. Diﬀerent substitutions
patterns can be obtained according to the reaction tem-
perature used (Figure 4). At room temperature the O-sub-
stitution is favored, while at higher temperature the N-
substitution is the preferred pathway. Taking into account
reaction conditions and reagents, diﬀerent derivatives can
be produced, that is, N-, O-, N,O-, or N,N-dicarboxymethyl
chitosan [48].
CMC nanoparticles were prepared as carriers for some
anticancer drugs. For example, Shi et al. used diﬀerent kinds
of CMC with various molecular weights and degrees of
substitution to prepare nanoparticles through ionotropic
gelification with calcium ions. These results showed the
feasibility of CMC nanoparticles to entrap doxorubicin and
the potential to deliver it following a controlled profile [49].
Anhitha et al. prepared curcumin-loaded O-CMC nanopar-
ticles (curcumin-O-CMC Nps) as a novel carrier in cancer
drug delivery applications. In L929, MCF-7, and PC-3 cell
lines, the O-CMC NPs without drug showed no cytotoxicity,
whereas curcumin and curcumin-O-CMC NPs resulted in
considerable cell death. Cellular uptake was analyzed by flu-
orescence microscopy. Control cells without any exposure
to NPs and cells incubated with O-CMC NPs showed no
fluorescence. Conversely, cells incubated with curcumin-
O-CMC NPs displayed green fluorescence, confirming the
internalization of the particles [46]. In another work, tea
polyphenols (TPs) were loaded into carboxymethyl chitosan
and chitosan hydrochloride [50]. In vitro studies showed that
TPs were controlled released fromnanoparticles in PBS at pH
7.4. In addition, the cell apoptosis rate was increased from
30% after 24 h to 62% at the end of 72 h, induced by loaded
nanoparticles.
CMC-based nanoparticles of varying average size (40–
400 nm diameter) were developed for intranasal immuniza-
tion [41]. An interesting finding of this study was that TMC-
MCC composite nanoparticles obtained by electrostatic
complexation of the two polymers with a positive surface
charge exhibited higher immune responses when compared
to chitosan, TMC, and MCC nanoparticles.
Li et al. prepared nanoparticles with oleoyl-carboxymeth-
yl chitosan encapsulating rifampicin as drug delivery systems
[51]. These nanoparticles were not tested for any specific
route of administration. But their pulmonary administration
could be a possibility to treat tuberculosis. Therefore, it is
necessary to carry out studies to test the feasibility of these
NPs as inhaled drug delivery systems.
3.3. N-Succinyl-Chitosan (NSC). NSC is a chitosan derivative
obtained by the incorporation of succinyl moieties into the
N-terminal group of the glucosamine units (Figure 5) [52].
Like other derivatives, NSC displays good water solubility in
a broad pH range, and it is considered biocompatible both
in vitro and in vivo. NSC was initially developed as a wound
dressing material combined with collagen. It is also recog-
nized as an excellent cosmetic ingredient (Moistfine liquid,
INCI name Chitosan Succinamide).
Some authors have used this chitosan derivative to pre-
pare anticancer-drug-loaded NPs. For example, Hou et al.
synthesized a new NSC derivative by means of microwave
irradiation. They entrapped successfully hydroxycamptothe-
cin (HCPT) into the NSC nanoparticles and observed tumor
targeting and significant suppression of tumor growth after
s.c. injection (close to the tumor) in mice bearing S180
sarcoma tumor [53]. Yan et al. prepared similar nanoparticles
loaded with 5-fluorouracil (5-FU) [54]. They evaluated
biodistribution and tumor targeting after i.v. administration
in Sarcoma 180-bearing mice. The 5-FU-loaded NPs were
biodistributed mainly in the tumor and liver, being found
small quantities in kidney and spleen [54]. Luo et al.
evaluated antitumor eﬀects of NSC nanoparticles (NSCNPs)
without drugs in K562 cells [55]. The results revealed that
NSCNP could inhibit the proliferation of K562 with an IC50
of 37.78, 14.26, 10.93, and 9.78 υg/mL at 12, 24, 36, and 48 h,
respectively. According to a cytomorphology study and the
analysis of DNA fragments, the antitumor eﬀect of NSCNP
is achieved by necrosis and apoptosis induction in K562
cells.
3.4. PEGylated Chitosan. Grafting of hydrophilic polymers
such as PEG onto chitosan is a well-known strategy to im-
prove the solubility and biocompatibility of chitosan as well
as to achieve lower recognition by the host immune system
and increased blood circulation time (Figure 6) [56]. These
PEG chains create a barrier layer to prevent the adhesion of
opsonins present in the blood, so that the particles can be
“invisible” to phagocytic cells.
Due to the advantages that PEG confers to chitosan,
chitosan-g-PEG copolymer has been prepared and utilized to
develop various types of nanocarriers for transmucosal drug
delivery. Chitosan-g-PEG nanoparticles have been prepared
by ionotropic gelation with TPP [57]. This system displayed a
high association eﬃciency (>78.6%) leading to insulin load-
ing values as high as 38.6%. Results of in vivo studies after
intranasal administration to healthy rabbits showed that the
plasma glucose levels fell sharply and remained at a low con-
centration for, at most, 2-3 h and returned to baseline after
5 h. Other studies have shown that, apart from the reduction
of the cytotoxicity, PEGylation of TMC led to improved
colloidal stability of polyplexes and significantly increased
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Figure 4: Chemical structure of diﬀerent types of carboxymethyl chitosan (CMC): (1) N-CMC, (2) N,N-CMC, (3) O-CMC, and (3) N,O-
CMC (showing the modification at the D-glucosamine unit).
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Figure 5: Chemical structure of N-succinyl-chitosan (showing the
modification at the D-glucosamine unit).
O
NH
NH
O
OX
O
OO
MeO
O
HO
HO
O
OH
OH
O
OMeO
(1)
(2)
n
n
Figure 6: PEG-g-chitosan as obtained by the two most commonly
used synthetic routes: (1) reaction with an active ester derivative and
(2) reductive amination. X: linker.
cellular uptake compared to unmodified TMC [58]. These
improvements resulted in a significant, up to 10-fold, in-
crease of transfection eﬃciency in NIH/3T3, L929, and Me-
Wo cells.
Mao et al. prepared chitosan-DNA nanoparticles using a
complex coacervation process [59]. They conjugated PEG on
the nanoparticles and observed that the clearance of the
PEGylated nanoparticles in male AKR/J mice (6–8 weeks)
following intravenous administration was slower than that
of unmodified nanoparticles at 15min, with higher depo-
sitions in kidney and liver [59]. Other authors developed
a functional nanoparticulate carrier for DNA transfection
in asialoglycoprotein receptor overexpressed in HepG2 cells.
For this, they grafted a methoxy PEG (MPEG) and a receptor
ligand, lactobionic acid (LA) in chitosan [60]. They observed
that the system with ligand chitosan-(O-MPEG)-(N-LA)
showed better transfection eﬃciency (45.3%) than ligand-
free chitosan-(O-MPEG) (19.8%).
3.5. Thiolated Chitosan. Thiol modifications to chitosan and
nanoparticles derived from it have been aimed to localize a
drug delivery system at a given target site (Figure 7). Re-
cently, it was documented that thiolated chitosan has strong
mucoadhesive properties ascribed to the formation of disul-
fide bonds with cysteine-rich domains of mucus glycopro-
teins, leading to an improvement in mucoadhesion of up
to 140-fold when compared to unmodified chitosan [61].
Insulin-loaded nanoparticles prepared with chitosan-N-
acetyl-L-cysteine were found to improve the systemic absorp-
tion of insulin after nasal administration [62]. Although
the exact mechanism for the enhanced eﬀectiveness of this
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Figure 7: Thiolated chitosan: (1) general structure of thiolated
chitosan as modified by an –SH group and (2) chitosan-N-acetyl-
cysteine (showing the modification at the D-glucosamine unit). X:
linker.
system remains unclear, it was speculated that the mucoad-
hesive and permeation-enhancing properties based on disul-
fide bond “anchorage” increase the accessibility of insulin
molecules to the epithelial membrane and, hence, facilitates
the absorption of the protein across the nasal epithelium.
4. Chitosan-Based Polymeric Micelles for
Pulmonary Drug Delivery
Micelles are spherical nanosized colloidal dispersions with
a hydrophobic core and hydrophilic shell, composed by
am-phiphilic molecules which self-assembly under certain
concentration and temperature conditions (Figure 8). The
concentration and the temperature above which the mono-
mers turn in micelles are called critical micelle concentration
(CMC) and critical micellization temperature (CMT), re-
spectively [63]. The self-assembly of amphiphilic molecules
in water is driven by a gain in entropy of the solvent mol-
ecules and a decrease of free energy in the system as the
hydrophobic components withdraw from the aqueousmedia
[64]. Two forces are involved in the micelle formation, an
attractive force that leads to the association of molecules
and a repulsive force that prevents unlimited growth of the
micelles [65]. Micelles can be used as drug delivery systems,
especially for poorly water-soluble drugs that are incorpo-
rated into the micelle core. Like liposomes, polymeric mi-
celles allow the encapsulation of drugs with diﬀerent pol-
arities. Water-soluble drugs are adsorbed on the micelle
surface, and drugs with intermediate polarity are distributed
along the amphiphilic molecules [66]. However, they are
more stable than liposomes. Furthermore, due to its general
small size, micelles have the ability to penetrate tissues,
showing also a high encapsulation eﬃciency and possibility
of sterilization by filtration [63, 66, 67].
Recently, much attention has been given to polymeric
micelles formed by lipid polymer or block copolymers, gen-
erally di- and triblock copolymers, as drug delivery systems.
Compared to micelles prepared from conventional deter-
gents, polymeric micelles present a lower CMC value, mak-
ing them more physically stable, both in vitro and in vivo,
CMT
CMC
Figure 8: Formation ofmicelles by self-assembly of polymermono-
mers above critical micelle concentration (CMC) and critical
micellization temperature (CMT).
even under dilutions to final concentration below the CMC
[68]. Many studies have been published in the last years
regarding the use of polymeric micelles as solubilization
agents and bioavailability enhancers of diﬀerent drugs, with
emphasis on poorly soluble anticancer drugs [69–73]. They
have also been studied as carriers of genetic material [74]
and diagnostic agents [75]. Due to its size, generally lower
than 200 nm, and hydrophilic surface, micelles are poorly
recognized by the reticuloendothelial system (RES) and
present long circulation times in bloodstream with enhanced
permeability and retention eﬀects (EPR eﬀect) at solid
tumor sites or another areas with leaky vasculature such
infarcts, infections, and inflammations, for passive targeting
[76, 77]. It is also possible to promote the targeting of
drugs to specific organs and tissues using stimuli-responsive
micelles [77–79] or modulating the micellar surface with
active-targeting ligands [77, 80]. By sharing some structural
and functional features with natural transport systems, for
example, virus and lipoproteins, polymeric micelles can be
a useful strategy to solve the problem of drug resistance
[81].
Diﬀerent polymeric micelles have been developed, in the
last years, for pulmonary administration of various drugs
to treat diﬀerent diseases such as cancer [82], inflammation
conditions [83], and pulmonary infections [84–86]. They
have been also studied as carriers of genetic material to treat
cystic fibrosis [87]. In this section, we will focus on chitosan-
based polymeric micelles as drug carriers.
4.1. Chitosan-Based Micelles. Due to its cationic nature, chi-
tosan can be complexed with negatively charged DNA and be
used as nonviral vector for gene therapy. Hu and coworkers
synthesized stearic acid- (SA-) grafted chitosan oligosaccha-
ride (CSO) in order to produce polymeric micelles to deliv-
ery pDNA (pEGFP-C1) [88]. The SA-CSO/DNA micelles
eﬃciently protected the condensed DNA from enzymatic
degradation by DNAse I and presented lower cytotoxicity
and comparable transfection eﬃciency in A549 cells com-
pared to Lipofectamine 2000 [88], making these micelles
a promising gene delivery system in the treatment of pul-
monary diseases. The same research group developed SA-
CSO micelles for the delivery of drugs like paclitaxel [89],
doxorubicin [90, 91], and proteins [92]. The encapsulation
of doxorubicin in SA-CSO micelles resulted in higher uptake
and accumulation by A549 cells and a decrease in the IC50
[20]. Recently, SA-CSO micelles were developed by another
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research group, for the pulmonary administration of ampho-
tericin B (AmB) [93]. The local administration of AmB to
treat invasive pulmonary fungal infections, present in some
patients receiving immune suppressive treatments, avoids the
systemic side eﬀects and improves the bioavailability of the
drug [94]. After encapsulation into micelles, AmB presents
the same antifungal activity of Fungizone but lower toxicity
[93], a phenomenon intimately related to its aggregation
state [95]. The micelles possessed positive charges with mean
diameters between 100 and 250 nm and were eﬃciently
nebulized using an Air-jet nebulizer presenting up to 52%
of fine particle fraction, making them a suitable choice for
pulmonary delivery of AmB [93].
In the field of block copolymers, Liu and coworkers de-
veloped an triblock copolymer consisting of poly(ε-caprolac-
tone)-b-chitooligosaccharide-b-poly(ethylene glycol) (PCL-
b-COS-b-PEG) for delivery of drugs, using doxorubicin as
model drug [96]. The obtained polymer presents the capacity
to formmicelles with encapsulation eﬃciency of doxorubicin
close to 50%. Genipin after crosslinking did not aﬀect the
macroscopic characteristics of the micelles but delayed the in
vitro release of doxorubicin from the micellar reservoir [96].
Similar results were obtained by Chen et al. using chitosan-
poly(ε-caprolactone)-poly(ethylene glycol) to encapsulate
paclitaxel and rutin with glutaraldehyde after crosslinking
[97]. Wu and co-workers also synthesized chitosan-based
copolymers for drug delivery [98]. Polylactide- (PLA-) chi-
tosan copolymers with diﬀerent molar ratios were developed
and characterized. Rifampicin was used as lipophilic drug
model to be encapsulated. As PLA molar ratio increased,
the micelle size and drug-loading content increased, and the
rifampicin release rate decreased [98]. The present systems
were not tested for any specific route of administration.
Besides the creation of lipid-chitosan and polymer-chi-
tosan conjugates, it is also possible to produce chitosan de-
rivatives with amphiphilic characteristics that may self-as-
semble in aqueous environment and form polymeric micelles
[99–101]. Zhang and co-workers synthesized diﬀerent chi-
tosan derivatives composed by long-chain alkyl groups as
hydrophobic moieties and sulfated groups as hydrophilic
moieties to delivery of paclitaxel [102]. Between the dif-
ferent derivatives, N-octyl-O-sulfate chitosan presented the
best results in terms of solubilization of paclitaxel [102].
Paclitaxel-loaded micelles prepared with N-octyl-O-sulfate
chitosan had high drug-loading capacity and encapsulation
eﬃciency, were shown to be safe for intravenous injection,
and presented similar antitumor eﬃcacy as Taxol, but signif-
icantly reduced toxicity and improved bioavailability [103].
They also synthesized N-alkyl-N-trimethyl chitosan deriva-
tives to deliver 10-hydroxycamptothecin. The best results in
terms of encapsulation eﬃciency, stability, release behavior,
and pharmacokinetic properties were obtained with N-
octyl-N-trimethyl chitosan (degree of octyl and trimethyl
substitution is 8% and 54%, resp.) [104]. Another research
group studied the feasibility of N-succinyl-N-octyl chitosan
as delivery system of doxorubicin [105]. Although these sys-
tems have been tested for intravenous administration, they
present antitumor eﬃcacy against lung cancer cell lines such
as Lewis lung cancer cells [103] and A549 cells [103, 105].
Their pulmonary administration could be a possibility to
treat locally lung cancer; however, studies are required to
access its feasibility as inhaled drug delivery systems.
Chitosan-based polymeric micelles have also been devel-
oped as drug delivery systems for other routes of administra-
tion than pulmonary, with emphasis on intravenous admin-
istration of paclitaxel. Examples are the N-mPEG-N-octyl-
O-sulfate chitosan micelles produced by Qu and co-workers
[106], the N-lauryl-carboxymethyl-chitosan micelles devel-
oped by Miwa et al. [107], and the N-octyl-N-(2-carboxyl-
cyclohexamethenyl) chitosan micelles produced by Liu and
co-workers [108]. Other chitosan-based micelles have been
developed such as the doxorubicin-loaded linoleic acid-
grafted chitosan oligosaccharide micelles produced by Du et
al. for intercellular antitumor drug delivery to drug resistance
tumor cells [109, 110] or the methoxy poly(ethylene glycol)-
grafted chitosan micelles for delivery of methotrexate to treat
colon carcinoma [111, 112].
5. Chitosan-Ligand Conjugates for
Nanoparticle-Based Active Target Drug
Delivery Systems
As discussed in previous sections, chitosan is an ideal natural
polymer for the design and development of drug delivery
systems structured at micro- and nanoscopic scales. Par-
ticularly, its mucoadhesiveness [113, 114], biocompatibility
[115, 116], and capacity to promote the absorption of
poorly absorbable macromolecules across epithelial barriers
by transient widening of cell tight junctions thus modifying
the parallel transport [117–120] have been exploited in the
development of nanocarrier systems for transmucosal deliv-
ery. A recognized feature of chitosan-based nanostructured
systems is their capacity to protect sensitive therapeutic
macromolecules against degradation and their ability to
overcome mucosal barriers. As a consequence, their appli-
cation has been centered particularly in noninvasive routes
of administration including transmucosal administration of
proteins [121–125] and genetic material [126–130].
The capacity of chitosan to undergo multiple chemical
modifications has been exploited to increase the active tar-
geting of chitosan-based nanocarriers particularly for protein
and genetic material delivery towards specific cells [126,
131]. The modifications have comprised from derivatization
with small functional groups or substructures (e.g., thiolated
derivatives, grafted PEG) to conjugation with biologically
active ligands such as carbohydrates (e.g., galactose, man-
nose) or specific ligands such as folate, transferrin, or KNOB
viral protein. Nanocarrier systems of this kind with improved
biological and biopharmaceutical performance have been
the subject of active research in the past decade or so, as
discussed, with reference to specific systems, in the following
sections.
5.1. Conjugation of Sugar Ligands. Strategies to improve the
targeting potential of chitosan have addressed its function-
alization with sugar moieties, mostly with D-galactose and
D-mannose. Galactose groups were chemically bound to
8 International Journal of Carbohydrate Chemistry
chitosan aiming to achieve liver target delivery, while dextran
was grafted to enhance the stability of the complex in aque-
ous media. The system was found eﬃcient to transfect liver
cells expressing asialoglycoprotein receptor (ASGRr), which
specifically recognizes the galactose ligands on modified
chitosan [132]. Galactosylated chitosan-graft-PEG (GCP)
was developed for the same purpose. GCP-DNA complexes
were found to be stable due to hydrophobic shielding by PEG
and increased the stability against DNAse degradation. This
system was found to enhance the transfection of HepG2 cells
having ASGRr, thus indicating that galactosylated chitosan
is an eﬀective hepatocyte-targeted gene carrier [132]. This
same system was tested in vivo by a diﬀerent group.
Glycoconjugated chitosan was designed for ASGRr-directed
delivery to liver parenchymal cells. It was found that this
system has the potential to be a vector for targeting to
Kupﬀer cells in vivo. Other chitosan glycoconjugates have
incorporated lactose to develop gene nanocarriers. HeLa
cells were eﬀectively transfected by this nanocarrier system,
but neither HepG2 nor BNL CL2 cells. TEM evidence was
consistent with the proposal that the nanocomplexes were
internalized by HeLa cells and located inside endocytotic
vesicles and endosome-like compartments [133]. In turn,
eﬀorts have been made to target mannose receptors on
dendritic cells residing in tumors; hence, chitosan has been
functionalized with mannose. Using these nanoparticles in
the delivery of a plasmid encoding IL-12 resulted in enhanced
IL-12 gene transfer eﬃciency, suppressed tumour growth
and angiogenesis in the carcinoma BALB/c mouse model
[134]. A trisaccharide branch was attached onto chitosan
chain in order to target lectins on the cell surface in lung
tissues [135]. This modification increased the carrier uptake
and transfection eﬃciencies in various in vitro assays as
well as in mouse lung tissue as recently reviewed elsewhere
[136].
5.2. Conjugation of Folate. Folic acid (FA) is appealing as a
ligand for targeting cell membrane and allowing nanoparti-
cle endocytosis via the folate receptor (FR) for higher trans-
fection yields. Importantly, the high aﬃnity of folate to bind
its receptor (1 nM) [137] and folate small size allows its use
for specific cell targeting. Moreover, the ability of FA to bind
its receptor to allow endocytosis is not altered by covalent
conjugation of small molecules [138]. Folate receptor (FR) is
over-expressed on many human cancer cell surfaces, and the
nonepithelial isoform of FR (FRb) is expressed on activated
synovial macrophages present in large numbers in arthritic
joints [139]. Hence, folate conjugation to the surface of
chitosan and chitosan-derivatives-based nanoparticles has
been one of the actively studied strategies to vectorize drugs
over the past few years [140–149]. These systems have been
developed with a view to achieve targeting eﬀect in the
delivery of cytostatic drugs to tumor cells, genetic material,
or antiarthritis therapies and also for diagnostic and imaging
purposes. To this end, the majority of in vitro studies have
been conducted in various types of cell lines well known
to overexpress the human folate receptors (FRa and FLRb),
such as HeLa [145], HT29 [143], Caco-2 [143], B16F1 [150],
KB [151, 152], HepG-2 [153], and SKOV3 [141, 154] cells.
The evidence from most of these studies is consistent to
indicate that the folic acid modification promotes the uptake
of nanoparticles by FR-positive tumor cell lines most likely
via receptor-mediated endocytosis but has little impact on
other cells without FR [155]. Results of transfection studies
showed that folate-chitosan-based nanoparticles enhanced
the reporter gene expression against a cell line overexpressing
FR (SKOV3 cells) compared to an FR-deficient cell line
(A549 cells) and did not induce obvious cytotoxicity against
HEK 293 cells [154]. In turn, NPs made out of folate-
grafted chitosan were produced to transfect interleukin-1
receptor antagonist (IL-1Ra) in synovial mononuclear cells
and CD14+ cells via the targeting of the folate receptor-b
[156]. Compared to unmodified chitosan or naked DNA,
this system allowed for an increase in IL-1Ra expression
combined with a diminution of cytotoxicity in vitro and
reinforced protection against inflammation and abnormal
bone metabolism in vivo.
5.3. Conjugation of Protein Ligands. Proteins, such as trans-
ferrin and viral KNOB, have been conjugated at the surface of
chitosan-based nanoparticles intended for DNAdelivery, as a
strategy to achieve active targeting and thus high transfection
eﬃciency [59, 157]. The transferrin receptor (TfR) is found
in many mammalian cells, responsible for iron import to
cells, and it is known to enhance the transcytosis of viral
vector [158, 159]. Transferrin (Tf) or antibodies against TfR
were conjugated to oligonucleotides or polycations, which
then complexed with pcDNA. Two diﬀerent synthetic ap-
proaches were tested to couple Tf to the surface of chitosan
nanoparticles, achieving a conjugation in both cases about
33–43% (transferrin to chitosanmoL%) [59]. In this study
HEK293 cells were transfected using luciferase reporter gene.
Tf-conjugated nanoparticles invariably showed threefold
greater transfection eﬃciency than unmodified nanoparti-
cles. However, the Tf-decorated nanoparticles did not show
significant enhancement of the transfection of HeLa cells
[160].
Tf decoration of chitosan-based DNA-loaded nanoparti-
cles has been found to enhance the transport across polarized
monolayer Caco-2 cells known to have abundant Tf receptors
on their surface [159] and extensively used as a model of
normal intestinal epithelium transport [161]. It was demon-
strated that Tf conjugation could enhance the transport
of nanoparticles through Caco-2 alone and Caco-2-PPL
cocultures by 3- to 5-fold. One drawback of these systems
is that they only proved to be ineﬀective in the presence of
added serum medium. An interesting contribution of this
study was to address the behavior of a coculture of polarized
Caco-2 cells infiltrated with lymphocytes that induces the
diﬀerentiation of M-type phenotype, a model much closer
to the real intestinal epithelium. The results led to suggest
that uptake in the lymphoid follicles of the duodenum could
play a more significant role compared to Peyer’s patches
[157].
A second related strategy has been to decorate the surface
of DNA-loaded chitosan-based nanoparticles with KNOB
protein so as to enhance the uptake and overcome one of
the major rate-limiting steps for transfection mediated by
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chitosan nanoparticles via a specific receptor-mediated en-
docytosis mechanism [59]. KNOB conjugation to the nano-
particles significantly improved the transfection eﬃciency
(increased 130 times) when transfecting HeLa cells but still
not to a level that could rival Lipofectamine transfection.
5.4. Hybrid Nanoparticles Comprising Other Polysaccharides.
Yet another approach to enhance the targeting capacity of
chitosan-based nanocapsules has been to develop hybrid co-
gelled systems including other polysaccharides with known
aﬃnity toward specific receptors. Among these, nanoparti-
cles comprising hyaluronan, alginate, and glucomannan have
deserved attention, particularly for the delivery of insulin,
vaccines, and DNA via transmucosa. The reader is referred to
recent comprehensive reviews on the subject [125, 127, 162].
6. Conclusion
Pondering advantages and drawbacks, chitosan-based mate-
rials represent a very versatile and appealing technological
platform to address the design of drug delivery systems
that combine unique features such as mucoadhesiveness and
enhanced drug absorption for the localized and systemic
delivery of drugs through the respiratory system. Further-
more, in a more global perspective that values the potential
of the bench-to-bedside translation, relatively low price,
commercial availability in a broad spectrum of molecular
weights and degrees of deacetylation and chemical versatility
are outstanding properties that make of chitosan an excellent
candidate in an industrial setting. On the other hand, the
lack of reproducibility between batches usually displayed by
natural polymers might lead to a less robust production pro-
cess and remains a challenge to be addressed and overcome.
Finally, to date chitosan is approved only as food supplement
classified as a “generally recognized as safe” (GRAS) material
[4]. In the context of pharmaceutical and biomedical prod-
ucts, a diversity of systems (e.g., micro- and nanoparticles,
films, scaﬀolds, etc.) is under investigation. Remarkably,
none of them has been approved by regulatory agencies
yet. The diversity of molecular aspects that might aﬀect
the biodegradability, biodistribution, and biocompatibility
needs to be carefully investigated as straight extrapolations
among derivatives seem very complex, if not impossible.
Hence, the regulatory phase will also need to be comprehen-
sively addressed if an eﬀective technology transfer and novel
endeavors want to be ensured for chitosan and its derivatives.
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